Skip to main content
Clinical Trials/NCT04948697
NCT04948697
Completed
Phase 2

A Phase 2, Randomized, Open-labeled Clinical Study Investigating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab Plus BAT1706 and of Tislelizumab Plus BAT1706 as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

BeiGene28 sites in 2 countries94 target enrollmentAugust 20, 2021

Overview

Phase
Phase 2
Intervention
Ociperlimab
Conditions
Not specified
Sponsor
BeiGene
Enrollment
94
Locations
28
Primary Endpoint
Objective Response Rate (ORR) as Assessed by the Investigator
Status
Completed
Last Updated
last year

Overview

Brief Summary

This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).

Registry
clinicaltrials.gov
Start Date
August 20, 2021
End Date
February 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
BeiGene
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically confirmed HCC
  • Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease that was not amenable to or had progressed after loco-regional therapy, and was not amenable to a curative treatment approach
  • Tumor tissue required for an evaluable programmed cell death protein-ligand 1 (PD-L1) expression result
  • No prior systemic therapy for HCC
  • At least 1 measurable lesion as defined per RECIST v1.1
  • Adequate organ function during screening and before randomization

Exclusion Criteria

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
  • Prior therapy with antibody or drug specifically targeting T-cell costimulation or checkpoint pathway; prior treatment with bevacizumab or its biosimilars
  • Prior history of \>= Grade 2 hepatic encephalopathy
  • Leptomeningeal disease or uncontrolled, untreated brain metastasis
  • Active autoimmune diseases or history of autoimmune diseases that may relapse
  • History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases
  • Infection (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days of randomization
  • Prior allogeneic stem cell transplantation or organ transplantation
  • Significant cardiovascular risk factors
  • Untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding

Arms & Interventions

Arm A: Ociperlimab + Tislelizumab + BAT1706

Participants received tislelizumab 200 milligrams (mg) intravenously once every 3 weeks followed by BAT1706 15 milligrams per kilogram (mg/kg) intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

Intervention: Ociperlimab

Arm A: Ociperlimab + Tislelizumab + BAT1706

Participants received tislelizumab 200 milligrams (mg) intravenously once every 3 weeks followed by BAT1706 15 milligrams per kilogram (mg/kg) intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

Intervention: Tislelizumab

Arm A: Ociperlimab + Tislelizumab + BAT1706

Participants received tislelizumab 200 milligrams (mg) intravenously once every 3 weeks followed by BAT1706 15 milligrams per kilogram (mg/kg) intravenously once every 3 weeks followed by ociperlimab 900 mg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

Intervention: BAT1706

Arm B: Tislelizumab + BAT1706

Participants received tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

Intervention: Tislelizumab

Arm B: Tislelizumab + BAT1706

Participants received tislelizumab 200 mg intravenously once every 3 weeks followed by BAT1706 15 mg/kg intravenously once every 3 weeks in 21-day treatment cycles until disease progression, unacceptable toxicity, or withdrawal for other reasons, whichever occurred first.

Intervention: BAT1706

Outcomes

Primary Outcomes

Objective Response Rate (ORR) as Assessed by the Investigator

Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months)

ORR was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response evaluation criteria in solid tumors version(v) 1.1 (RECIST v1.1). Per RECIST v1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcomes

  • Duration Of Response (DOR) as Assessed by the Investigator(From the first confirmed objective response until the first documentation of disease progression or death, whichever came first (i.e. up to 27 months))
  • Time to Response (TTR) as Assessed by the Investigator(From the randomization date to the first documentation of response (up to 27 months))
  • Disease Control Rate (DCR) as Assessed by the Investigator(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months))
  • Clinical Benefit Rate (CBR) as Assessed by the Investigator(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first (i.e., up to 27 months))
  • Progression-Free Survival (PFS) as Assessed by the Investigator(From the randomization date to the date of first documentation of disease progression or death, whichever came first (i.e., up to 27 months))
  • Overall Survival (OS)(From the randomization date until the date of death from any cause (up to 27 months))
  • Number of Participants With Treatment Emergent Adverse Events (TEAEs)(From the date of the first dose of study drug up to 30 days after last dose of study drug (i.e., up to 27 months))
  • Serum Concentrations of Ociperlimab(Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days))
  • Serum Concentrations of Tislelizumab(Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days))
  • Serum Concentrations of BAT1706(Predose on Day 1 of Cycles 1, 2, 5, 9 and 17; Post dose on Day 1 of Cycles 1 and 5 and Safety Follow-up Visit (i.e., up to 30 days after last dose [up to 27 months]) (each cycle duration = 21-days))
  • Number of Participants With Antidrug Antibodies (ADAs) to Ociperlimab, Tislelizumab, and BAT1706(Up to 27 months)

Study Sites (28)

Loading locations...

Similar Trials